secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2026-06-18T20:50:36+00:00
Accession:  0001824293-26-000050
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio receives FDA Orphan Drug Designation for GRI-0621 in IPF
----------------------------------------------------------------

- FDA granted Orphan Drug Designation to GRI-0621 for idiopathic pulmonary fibrosis.
- Designation provides potential 7-year U.S. market exclusivity upon approval.
- GRI-0621 is an oral RARβ/γ selective agonist that met endpoints in Phase 2a trial (35 patients).
- IPF affects fewer than 200,000 U.S. patients; significant unmet medical need exists.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429326000050/0001824293-26-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429326000050/val-20260618.htm
  HTML page:      https://secwatch.observer/filing/0001824293-26-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer